Laura Mezquita, Hospital Clinic Barcelona, Barcelona, Spain, discusses a retrospective study of estimated indoor radon levels and the regional prevalence of driver alterations in patients with non-small cell lung cancer (NSCLC). Patients with EGFR/ALK/BRAF/HER2/KRAS alterations were identified and the radon concentration where they were born was recorded. The results from almost 4000 patients showed that adenocarcinoma histology and non-smoker history were more common in the high-radon group than the low-radon group. When analyzing the presence of driver alterations, no significant difference was seen once age, gender and smoking had been adjusted for. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
DISCLOSURES
Research grants/funding: Bristol Myers Squibb, Boehringer Ingelheim, Amgen
Advisory/Consultancy: Roche Diagnostics, Takeda
Honoraria: Bristol Myers Squibb, Tecnofarma, Roche
https://www.vjoncology.com/video/htl6rgs0er4-bioradon-france-levels-of-radon-and-prevalence-of-driver-alterations-in-nsclc/
Travel/Accommodation/Expenses: Roche
Laura Mezquita • 29 Jan 2021 WCLC 2021 LUNG CANCER NON-SMALL CELL LUNG CANCER BIORADON FRANCE
STUDY
64